ADC

77개 · ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-4 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved77 programs
ADCLimited DatastaleSeagenPreclinical

Brentuximab-Vedotin associated with Bendamustine (Brentuximab-Vedotin associated with Bendamustine)

Relapsed or Refractory Hodgkin Lymphoma · FRα

#FR#ADC#Preclinical#antibody-drug-conjugate#RelapsedorRefractoryHodgkinLymph+1
Trials 1Status Active
ADCLimited DatastaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin and Toripalimab)

Muscle Invasive Bladder Cancer; HER2 Expression · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#MuscleInvasiveBladderCancer+2
Trials 1Status Active
ADCLimited DatastaleSeagen, a wholly owned subsidia…Phase 1

Felmetatug Vedotin (Felmetatug Vedotin)

Ovarian Neoplasms; Peritoneal Neoplasms · HER2

#HER2#ADC#Phase1#antibody-drug-conjugate#OvarianNeoplasms+2
Trials 1Status Discontinued
ADCLimited DatastalePfizerPhase 3

INO (Inotuzumab ozogamicin, Inotuzumab ozogamicin (INO))

B-Cell Acute Lymphoblastic Leukaemia · B-Cell Acute Lymphoblastic Leukaemia

#B-CellAcuteLymphoblasticLeukaemi#ADC#Phase3#antibody-drug-conjugate#Pfizer
Trials 1Status Recruiting
ADCLimited DatastaleGilead SciencesPhase 2

LG (Labetuzumab Govitecan, Labetuzumab Govitecan (LG))

Metastatic Colorectal Cancer; Colon Cancer · Metastatic Colorectal Cancer

#MetastaticColorectalCancer#ADC#Phase2#antibody-drug-conjugate#ColonCancer+1
Trials 1Status Discontinued
ADCLimited DatastaleAbbViePhase 1

Mirvetuximab + SL-172154 (Mirvetuximab + SL-172154)

Platinum-resistant Ovarian Cancer; Fallopian Tube Cancer · Platinum-resistant Ovarian Cancer

#Platinum-resistantOvarianCancer#ADC#Phase1#antibody-drug-conjugate#FallopianTubeCancer+1
Trials 1Status Active
ADCLimited DatastaleShengjing HospitalPhase 2

Next-generation Site-specific human epidermal growth factor receptor 2 (HER2, Next-generation Site-specific human epidermal growth factor receptor 2, Next-generation Site-specific human epidermal growth factor receptor 2 (HER2)-targeting Antibody-drug Conjugate (ARX788))

Breast Neoplasms · HER2

#HER2#ADC#Phase2#antibody-drug-conjugate#BreastNeoplasms+1
Trials 1Status Recruiting
ADCLimited DatastaleBioAtla, Inc.Phase 2

Ozuriftamab Vedotin (Ozuriftamab Vedotin)

Head and Neck Cancer; Squamous Cell Carcinoma of Head and Neck · Head and Neck Cancer

#HeadandNeckCancer#ADC#Phase2#antibody-drug-conjugate#SquamousCellCarcinomaofHeadandNe+1
Trials 1Status Active
ADCLimited DatastaleRochePhase 2

Polatuzumab vedotin, Glofitamab (Polatuzumab vedotin, Glofitamab)

Diffuse Large B-cell Lymphoma · Diffuse Large B-cell Lymphoma

#DiffuseLargeB-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleRochePhase 2

Polatuzumab, bendamustin und rituximab (Polatuzumab, bendamustin und rituximab)

Mantle-cell Lymphoma · Mantle-cell Lymphoma

#Mantle-cellLymphoma#ADC#Phase2#antibody-drug-conjugate#Roche
Trials 1Status Recruiting
ADCLimited DatastaleFudan UniversityPhase 2

Observational Cohort (Sacituzumab Tirumotecan, Sacituzumab Tirumotecan (Observational Cohort))

Bladder Cancer; Metastatic Urothelial Carcinoma · Bladder Cancer

#BladderCancer#ADC#Phase2#antibody-drug-conjugate#MetastaticUrothelialCarcinoma+1
Trials 1Status Recruiting
ADCLimited DatastaleThe First Affiliated Hospital o…Phase 2

sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Combined with Bevacizumab)

Platinum-resistant Recurrent Ovarian Cancer (PROC) · Platinum-resistant Recurrent Ovarian Can

#Platinum-resistantRecurrentOvari#ADC#Phase2#antibody-drug-conjugate#The
Trials 1Status Recruiting
ADCLimited DatastaleGlaxoSmithKlinePhase 2

Unconjugated belantamab antibody (Unconjugated belantamab antibody)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GlaxoSmithKline
Trials 1Status Recruiting
ADCLimited DatastaleGlaxoSmithKlinePhase 2

belantamab mafodotin (Blenrep, GSK2857916, Unconjugated belantamab antibody and belantamab mafodotin)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#ADC#Phase2#antibody-drug-conjugate#GlaxoSmithKline
Trials 1Status Recruiting
ADCLimited DatastaleAstellasPreclinical

pembrolizumab (Keytruda, enfortumab vedotin plus pembrolizumab in first line setting for advanced upper tract urothelial carcinoma)

Advanced Upper Tract Urothelial Carcinoma · Advanced Upper Tract Urothelial Carcinom

#AdvancedUpperTractUrothelialCarc#ADC#Preclinical#antibody-drug-conjugate#Astellas
Trials 1Status Active
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and CDX-301 (glembatumumab vedotin and CDX-301)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued
ADCLimited DatastaleCelldex TherapeuticsPhase 2

glembatumumab vedotin and varlilumab (glembatumumab vedotin and varlilumab)

Melanoma · Melanoma

#Melanoma#ADC#Phase2#antibody-drug-conjugate#Celldex
Trials 1Status Discontinued

4 / 4 pages

← PreviousNext →